drug

The FDA approval means that patients who have primary immunodeficiency will be able to self inject the drug--Gammagard Liquid--at home, if recommended by a doctor. Previously the drug was only accessible through intravenous infusi

Baxter said that new administration route would give patients greater flexibility in receiving treatments.

Baxter International (NYSE:BAX) announced Monday that a prescription drug for patients with dysfunctional immune systems has been approved for below-the-skin injection.

Vertex Pharmaceuticals (VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved its INCIVEK (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver di

Recalls at Johnson & Johnson(JNJ) mean big profit for Novartis (NVS). According to Chief Financial Officer Jon Symonds, he said the company's is benefitting in the consumer drug division and Novartis is reportedly interested

Glaxo is in settlement talks with attorneys for an estimated 1,000 former Avandia users.

Glaxo shares are down 0.42%, or $0.18, to $43.06.

Shares of GlaxoSmithKline (GSK) are down after Bloomberg, citing a lawyer for the patients, reported that the drug maker is set to resolve 1,000 more lawsuits over medicines, including the diabetes drug Avandia.

Health care shares are trending higher, while Abbott Laboratories (ABT) is seeing solid gains after reporting study results. In sector news, Abbott Laboratories (ABT) today announced that data from its Endovascular Valve Edge-to-E

Vivus (VVUS) is up by double digits in early trading, after it says long-term data demonstrated patients treated with the investigational drug QNEXA for two years showed reductions in blood pressure and the use of antihypertensive

Each stock option has an exercise price per share equal to $11.83, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commenceme

Optimer Pharmaceuticals (OPTR) says that on March 31, its Board approved the grant of inducement stock options to purchase an aggregate of 258,000 shares of common stock to 7 new employees.

The Centers for Medicare & Medicaid Services said that the $93,000 drug regiment is reasonable and necessary for men with advanced, castrate-resistant prostate tumors who have minimal or no symptoms of the disease.

Dendreon has a potential upside of 48.3% based on a current price of $35.54 and an average consensus analyst price target of $52.71.

Regulators said that Dendreon Corp.'s (NASDAQ:DNDN) prostate cancer drug Provenge should be covered by the U.S. government for use in older men, according to a Bloomberg report.

However, the FDA did say it may at any time revisit a decision to exercise enforcement discretion, leaving some room open for future regulatory enforcement regarding compounding the drug, Reuters reported.

K-V Pharmaceuticals (KV.A) slides after the FDA says it does not plan to take enforcement action against pharmacies that compound KV.A's pre-term birth drug based on a valid prescription.